Article from the Canada Communicable Disease Report (CCDR), Volume 36 • ACS-12, November 2010.
This statement supplements previous conjugate pneumococcal statements and provides information regarding a newly authorized conjugate vaccine against pneumococcal disease, Prevnar® 13 (PNEU-C-13). It is anticipated that adult pneumococcal immunization programs will be changing over the next few years, as other vaccines are in development and as new data on Synflorix™ (PNEU-C-10) and PNEU-C-13 is published. These vaccines and new indications for already authorized products will be reviewed in one or more additional statements once they are authorized or further indications are authorized for use in Canada. The 23-valent polysaccharide vaccine will not be discussed in this statement. Recommendations for its use remain unchanged.
This statement:
- reviews existing NACI recommendations on the use of conjugate pneumococcal vaccines;
- updates the epidemiology of pneumococcal disease in Canada relevant to the introduction of PNEU-C-13;
- provides an update on the conjugate pneumococcal vaccination schedules used in Canada;
- provides a literature review on the use of 3 doses (2 infant doses +1 booster) versus 4 doses (3 infant doses +1 booster) of conjugate pneumococcal vaccines;
- provides information on a newly licensed 13-valent vaccine against pneumococcal disease; and
- provides recommendations for the use of the 13-valent conjugate vaccine (PNEU-C-13).
Source: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-12/index-eng.php
- Americas
- Canada
- health policy
